Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

Executive Summary

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

You may also be interested in...



Lilly Oncology President Anne White On Loxo Success, What’s To Come

White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening. 

Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.

Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel